Using ultrasound to measure the size of the median nerve — which runs down the upper arm and continues into the forearm and hand…
News
The EveryLife Foundation for Rare Diseases has launched a scholarship fund in the U.S. to support individuals with rare disorders who are pursuing personal…
Treatment with Tegsedi (inotersen) eased a range of neuropathy symptoms in people with familial amyloid polyneuropathy (FAP), new data from the NEURO-TTR Phase 2/3 trial…
When the COVID-19 pandemic forced the postponement of a rare disease film festival originally slated for May, its organizers set out to find…
Treatment with Tegsedi (inotersen) slows neurological disease progression in people with familial amyloid polyneuropathy (FAP), results from a Phase 2/3 clinical trial show.
Long-term treatment with Onpattro (patisiran) safely and effectively halts or reverses disease progression in people with familial amyloid polyneuropathy (FAP), final data from…
Magnetization transfer ratio (MTR), an MRI scanning tool based on nerve imaging, may help diagnose familial amyloid polyneuropathy (FAP) in…
The EveryLife Foundation for Rare Diseases has launched a nationwide National Burden of Rare Disease Survey to measure the full implications, economic and…
Levels of calprotectin, a marker of inflammation, are elevated in the feces of people with familial amyloid polyneuropathy (FAP) who experience gastrointestinal (GI)…
The Italian Medicines Agency has added Tegsedi (inotersen), a treatment for familial amyloid polyneuropathy (FAP), to the list of reimbursed therapies in…
Recent Posts
- New analyses back Amvuttra as first-line treatment for complex heart cases
- Injection therapy Wainua offers ‘ray of hope’ for hATTR-PN patients
- Understanding the patient’s perspective in a fast-paced world
- Attruby may reduce outpatient heart failure worsening in ATTR-CM
- Being a caregiver means becoming an expert on your loved one’s disease